Moderna News

Moderna | DEFA14A: Others

Mar 21 08:51 ET

Moderna | DEF 14A: Definitive information statements

Mar 21 08:51 ET

Moderna | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Mar 11 16:10 ET

Moderna | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Feb 23 16:28 ET

Moderna | 8-K: Moderna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates

Feb 22 06:36 ET

Moderna | 8-K: Updates of Progress on the Pipeline of Transformative mRNA Medicines and Preliminary Financial Results

Jan 8 00:00 ET

Moderna | 8-K: Moderna announces that Arpa Garay Will Leave His Position

Dec 12, 2023 08:04 ET

Moderna | 8-K: Chief Commercial Officer Arpa Garay Cancelled the Garay 10b5-1 Plan on November 6, 2023

Nov 6, 2023 08:02 ET

Moderna | 8-K: Moderna Reports Third Quarter 2023 Financial Results

Nov 2, 2023 06:33 ET

Moderna | 8-K: Moderna Statement on Anticipated 2023 COVID-19 Sales

Oct 16, 2023 08:59 ET

Moderna | 8-K: Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics

Sep 11, 2023 08:08 ET

Moderna | 8-K: Moderna Reports Second Quarter 2023 Financial Results

Aug 3, 2023 06:33 ET

Moderna | 8-K: Notice of the 2023 Annual Meeting of Stockholders

May 5, 2023 16:05 ET

Moderna | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers

May 5, 2023 07:31 ET

Moderna | 8-K: Moderna Reports First Quarter 2023 Financial Results

May 4, 2023 06:33 ET

Moderna | DEFA14A: Others

Apr 14, 2023 10:58 ET

Moderna | DEFA14A: Others

Mar 15, 2023 16:17 ET

Moderna | DEF 14A: Definitive proxy statements

Mar 15, 2023 16:16 ET

Moderna | 8-K: Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Feb 23, 2023 07:03 ET

Moderna | 8-K: Moderna Announces Advances Across mRNA Pipeline and Provides Business Update

Jan 9, 2023 07:03 ET